title: PAPP-A: a promising therapeutic target for healthy longevity.
abstract: Pregnancy-associated plasma protein-A (PAPP-A) is a proteolytic enzyme that was discovered to increase local insulin-like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP-A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP-A as a therapeutic target to promote healthy longevity.
authors.affiliation: Endocrinology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Conover
authors.affiliation: Department of Molecular Biology and Genetics, Aarhus Universitet, Aarhus, Denmark.
authors.forename: Claus
authors.initials: C
authors.lastname: Oxvig
mesh_terms: D004194:Disease; D006262:Health; D006801:Humans; D008136:Longevity / Q000502:physiology*; D058990:Molecular Targeted Therapy; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D011266:Pregnancy-Associated Plasma Protein-A
keywords: 
  IGF
  ; PAPP-A; aging